Porrima

Porrima (now rebranded as Cytodigm) is a biotechnology company focused on the development of advanced nanoparticle delivery systems for oncology and genetic medicine. Headquartered in Boston, the company specializes in proprietary PEG-free lipid nanoparticles (LNPs) and polymer nanoparticles (PNPs) designed to overcome significant biological hurdles, such as the blood-tumor barrier. Its lead development program, PPRX-1701, is a polymer-based nanoparticle therapy that aims to improve drug delivery and therapeutic outcomes in glioblastoma multiforme (GBM). Porrima's platform technology is designed to reduce immunogenicity and toxicity while enabling precise tissue-specific targeting for a variety of payloads, including nucleic acids, proteins, and small molecules.